Stockscreener 앱 받기
46.95
1.55%
-0.74
시장 영업 전:
47.30
0.35
+0.75%
Crispr Therapeutics Ag 주식(CRSP)의 최신 뉴스
CRISPR Therapeutics AG (CRSP) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance Singapore
Here is why CRISPR Therapeutics (CRSP) appears so good - MSN
CRISPR Therapeutics AG (CRSP) falls more steeply than broader market: What investors need to know - MSN
CRISPR Therapeutics AG (CRSP) Declines Sharply Compared to Overall Market: Essential Information for Investors - Bitget
CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo! Finance Canada
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It - MSN
CRISPR Therapeutics AG Bonds — Corporate Bond Rates - TradingView
Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock - MSN
(CRSP) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Piper Sandler raises CRISPR Therapeutics price target on cash raise By Investing.com - Investing.com South Africa
Volatility Watch: Is CRISPR Therapeutics AG showing insider buyingInsider Selling & Proven Capital Preservation Tips - baoquankhu1.vn
CRISPR Therapeutics (CRSP) Is Down 5.1% After $550M Convertible Notes OfferingHas The Bull Case Changed? - simplywall.st
Insider Selling: CRISPR Therapeutics (NASDAQ:CRSP) CEO Sells 10,349 Shares of Stock - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Insider Naimish Patel Sells 3,150 Shares of Stock - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) General Counsel James Kasinger Sells 3,450 Shares - MarketBeat
CRISPR Therapeutics (NASDAQ: CRSP) CMO vests RSUs, mandated tax sale - Stock Titan
CRISPR Therapeutics (NASDAQ: CRSP) CFO covers RSU taxes with share sale and gift - Stock Titan
CRISPR Therapeutics (NASDAQ: CRSP) GC sells shares for tax withholding - Stock Titan
CRISPR Therapeutics (CRSP) CEO logs RSU vesting and tax-driven share sale - Stock Titan
Crispr Therapeutics Completes $600 Million Convertible Notes Offering - The Globe and Mail
Goodwin Guides CRISPR Therapeutics On Pricing $550 Million Upsized Convertible Senior Notes Offering - Mondaq
Piper Sandler Raises Price Target for CRSP to $110, Reiterates O - GuruFocus
Is CRISPR Therapeutics (CRSP) the best gene-editing stock to buy now? - MSN
Is Crispr Therapeutics (CRSP) The Best Gene-Editing Stock to Buy Now? - Insider Monkey
CRISPR Therapeutics (NASDAQ:CRSP) Receives Overweight Rating from Piper Sandler - MarketBeat
Piper Sandler raises CRISPR Therapeutics price target on cash raise - Investing.com
CRISPR Therapeutics (NASDAQ: CRSP) sells $600M 2031 convertible notes - Stock Titan
CRISPR Therapeutics AG Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Ark Invest Increases Holdings in CRISPR Therapeutics (CRSP) - GuruFocus
Clough Capital Partners L P Makes New $1.49 Million Investment in CRISPR Therapeutics AG $CRSP - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
CRISPR Therapeutics prices $550M convertible notes offering By Investing.com - Investing.com Nigeria
Is CRISPR Therapeutics (CRSP) Pricing Reflecting Gene Editing Potential After Recent Share Pullback - Yahoo Finance
CRISPR Therapeutics’ CASGEVY Progress Reframes Growth And Valuation Story - Sahm
CRISPR Therapeutics shares drop after announcing convertible notes sale - MSN
Cathie Wood’s ARK Invest Buys $10M in CRISPR and PayPay on Thursday - MEXC
ARK Invest Allocates $10M to CRISPR Therapeutics and PayPay in Latest Trading Session - MEXC
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know - Yahoo Finance
Q2 EPS Estimate for CRISPR Therapeutics Lifted by Analyst - MarketBeat
Assessing CRISPR Therapeutics (CRSP) Valuation After Upsized US$550m Convertible Notes Offering - Sahm
Wall Street Analysts See CRISPR Therapeutics (CRSP) as a Buy: Should You Invest? - MSN
ARK Investment Acquires 113K Shares of Crispr Therapeutics (CRSP) - GuruFocus
Insider Selling: CRISPR Therapeutics (NASDAQ:CRSP) General Counsel Sells 2,800 Shares of Stock - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) CEO Samarth Kulkarni Sells 9,798 Shares - MarketBeat
CRISPR Therapeutics AG CEO Samarth Kulkarni Sells Shares - TradingView
CRISPR Therapeutics (CRSP) counsel sells 2,800 shares to cover RSU taxes - Stock Titan
CRISPR Therapeutics (CRSP) CEO RSU vesting and 9,798-share tax sale - Stock Titan
CRISPR Therapeutics plans $350M convertible notes offering By Investing.com - Investing.com Nigeria
Research Analysts Set Expectations for CRSP FY2028 Earnings - MarketBeat
CRISPR Therapeutics AG (CRSP) Falls Sharper Than Overall Market: Key Information to Note - Bitget
CRISPR Therapeutics AG (CRSP) dips more than broader market: What you should know - MSN
CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know - Yahoo Finance
CRISPR Therapeutics (CRSP) Reports $116M FY25 Revenue Driven by CASGEVY Growth - Insider Monkey
CRISPR Therapeutics Announces $350 Million Convertible Senior Notes Offering to Fund Gene-Editing Innovation - Minichart
CRISPR Therapeutics (CRSP) Sees Significant ARK Invest Purchase - GuruFocus
CRISPR Therapeutics (NASDAQ:CRSP) Sees Strong Trading VolumeHere's What Happened - MarketBeat
CRISPR Therapeutics prices $550 million convertible senior notes offering - The Pharmaletter
CRISPR Therapeutics (CRSP) Stock Plunges 10% as Cathie Wood’s ARK Invest Scoops Up Shares - MEXC
CRISPR Therapeutics (CRSP) Reports Wider Q4 Loss of $1.37/Share on Zero Revenue; Shares Plunge 10% - AlphaStreet
CRISPR Therapeutics (CRSP) Stock Drops 10% — Cathie Wood’s Ark Buys the Dip - MEXC
CRISPR Therapeutics (CRSP) Upsizes Convertible Note Offering to $550M - GuruFocus
1.20%
0.06%
자본화:
|
볼륨(24시간):